Clinical Trial Update: Rhubarb and Angiotensin Converting Enzyme Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial update on rhubarb in combination with an ACE inhibitor for diabetic kidney disease; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease
• Diabetic Nephropathy

Drugs mentioned

• Angiotensin-converting enzyme inhibitor (angiotensin-converting enzyme inhibitor)
• Rhubarb (Rheum palmatum)

Snippet

Sponsor: Wake Forest University | Conditions: Diabetic Kidney Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-11-15